Jove
Visualize
联系我们

相关概念视频

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

255
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
255

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Assessment of Recipient Renal Transplant Arterial Graft Supply in the Immediate Postoperative Period (≤1 week): A Systematic Review.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation·2026
Same author

Uncomplicated type B aortic dissection: Are US-based societal guidelines delaying science?

The Annals of thoracic surgery·2026
Same author

The rationale for a randomized trial for uncomplicated Type B aortic dissection.

Seminars in vascular surgery·2026
Same author

Equipoise: The basic necessity for conducting a trial on uncomplicated Type B aortic dissection.

Seminars in vascular surgery·2026
Same author

Are society guidelines the best we have?

Seminars in vascular surgery·2026
Same author

Should Type B intramural hematoma be treated like Type B aortic dissection? A narrative review.

Seminars in vascular surgery·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 17, 2026

Novel and Innovative Hybrid Technique for Type A Aortic Dissection
06:26

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

851

在不复杂的B型大动脉剖析当代随机对照试验:一个比较的方法分析.

Tasnia Rahman1, Colin D Bicknell2, Firas F Mussa3

  • 1Heart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland - tasnia.rahman@helsinki.fi.

The Journal of cardiovascular surgery
|September 19, 2025
PubMed
概括

胸内血管大动脉修复 (TEVAR) 正在与非复杂的B型大动脉剖析的最佳医学疗法进行评估. 目前正在进行的试验将澄清TEVAR在大动脉重塑中的作用和长期结果.

更多相关视频

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

12.2K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

509

相关实验视频

Last Updated: Jan 17, 2026

Novel and Innovative Hybrid Technique for Type A Aortic Dissection
06:26

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

851
Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

12.2K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

509

科学领域:

  • 心血管外科心血管外科
  • 血管医学 血管医学
  • 医疗技术评估 医疗技术评估

背景情况:

  • 不复杂的B型大动脉剖析 (uTBAD) 管理是争论的.
  • 最好的医学疗法 (BMT) 是传统的,但胸内血管大动脉修复 (TEVAR) 提供了潜在的重塑益处.
  • 关于TEVAR的生存,风险和耐久性的相互矛盾的证据限制了采用.

研究的目的:

  • 为了比较三个主要的随机对照试验 (IMPROVE-AD, EARNEST, SUNDAY) 评估tevar对uTBAD.
  • 分析试验设计,纳入标准,干预措施和结果措施.
  • 将TEVAR不断变化的作用置于背景,并为未来的临床实践提供信息.

主要方法:

  • 对三项正在进行的随机对照试验进行比较分析:IMPROVE-AD,SUNDAY和EARNEST.
  • 检查研究设计,患者队列,干预方案 (TEVAR与 BMT) 和结果措施.
  • 综合方法来预测对临床实践和指导方针的影响.

主要成果:

  • 在六年内,IMPROVE-AD评估了TEVAR与 BMT的死亡率和并发症,对1100名患者进行了评估.
  • 星期天专注于亚急性UTBAD,评估重塑,安全和生存.
  • EARNEST集结了临床,解剖学,经济和生活质量终点.

结论:

  • 预计IMPROVE-AD,SUNDAY和EARNEST的结果将对UTBAD管理指南产生重大影响.
  • 这些试验预计将改进TEVAR的患者选择标准.
  • 将澄清tevar在uTBAD的长期益处和风险,指导未来的治疗策略.